You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NKG2D-L

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Ovarian Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Mar 26, 2023

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Not yet recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Nov 15, 2023

AML Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • AML
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
  • +1 more
Feb 17, 2023

Advanced Solid Tumors Trial in Hangzhou (Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT))

Recruiting
  • Advanced Solid Tumors
  • Universal Chimeric Natural Killer Receptor Modified T-cells (CNK-UT)
  • Hangzhou, China
    First affiliated hospital, School of Medicine, Zhejiang Universi
Aug 3, 2023

Gastric Cancer, Pancreatic Cancer, Solid Tumor Trial in Beijing (KD-496)

Recruiting
  • Gastric Cancer
  • +2 more
  • KD-496
  • Beijing, China
    Chinese PLA General Hospital
Oct 13, 2022

Refractory Metastatic Colorectal Cancer Trial in Hangzhou (NKG2D CAR-NK)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • NKG2D CAR-NK
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Jan 16, 2022

CRC, Solid Tumor Trial in Beijing (KD-025)

Recruiting
  • CRC
  • Solid Tumor
  • KD-025
  • Beijing, Beijing, China
    Chinese PLA General Hospital
May 16, 2022

Refractory Metastatic Colorectal Cancer Trial in Guangzhou (CAR-T infusion)

Recruiting
  • Refractory Metastatic Colorectal Cancer
  • CAR-T infusion
  • Guangzhou, Guangdong, China
    The Third Affiliated Hospital of Guangzhou Medical University
Feb 9, 2022

Safety and Efficacy Trial in Sanhe (CAR-NK cells)

Recruiting
  • Safety and Efficacy
  • CAR-NK cells
  • Sanhe, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Feb 9, 2022

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Recruiting
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Xunyang Changchun Shihua Hospital
Nov 20, 2021

Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])

Not yet recruiting
  • Acute Myeloid Leukemia
  • NK cells
  • Talazoparib 1 MG [Talzenna]
  • (no location specified)
Jan 9, 2023

Cancer, Malignancy, Refractory Cancer Trial in Singapore (Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?d T

Not yet recruiting
  • Cancer
  • +3 more
  • Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
  • Singapore, Singapore
    National University Hospital
Mar 20, 2022

Advanced Solid Tumor Trial in Shanghai (IMC008)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, Shanghai, China
    Shanghai Changhai Hospital
Apr 19, 2023

Recurrent Glioblastoma Trial (NKG2D CAR-T)

Not yet recruiting
  • Recurrent Glioblastoma
  • NKG2D CAR-T
  • (no location specified)
Jan 16, 2021

COVID-19 Trial in Chongqing (NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells)

Recruiting
  • COVID-19
  • NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
  • Chongqing, China
    Chongqing Public Health Medical Center
Nov 16, 2020

Acute Myeloid Leukemia Trial in Hangzhou (NKG2D CAR T-cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • NKG2D CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
Dec 5, 2020

HER-2 Positive Advanced Solid Tumors Trial (D3L-001)

Not yet recruiting
  • HER-2 Positive Advanced Solid Tumors
  • D3L-001
  • (no location specified)
Jul 20, 2023

Hepatocellular Carcinoma, Glioblastoma, Medulloblastoma Trial in Jiujiang (NKG2D-based CAR T-cells)

Withdrawn
  • Hepatocellular Carcinoma
  • +3 more
  • NKG2D-based CAR T-cells
  • Jiujiang, Jiangxi, China
    Affiliated hospital of jiujiang university
Oct 18, 2020

Acute Vaso Occlusive Crisis (VOC) Trial in Washington (L-citrulline, Normal saline (0.9% NaCl) D5 ½)

Recruiting
  • Acute Vaso Occlusive Crisis (VOC)
  • Washington, District of Columbia
  • +1 more
Jan 26, 2023

Solid Tumor, Hepatocellular Carcinoma, Colorectal Cancer Trial in Nanjing (KD-025 CAR-T cells)

Not yet recruiting
  • Solid Tumor
  • +3 more
  • KD-025 CAR-T cells
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Sep 20, 2020

Retinal Deep PhenotypingTM

Recruiting
  • Healthy
    • Waterloo, Ontario, Canada
    • +2 more
    Jun 16, 2023

    Limbal Stem Cell Deficiency Trial in Toronto, Montréal, Québec (surgical transplantation of CECA)

    Recruiting
    • Limbal Stem Cell Deficiency
    • Surgical transplantation of ACCE
    • Toronto, Ontario, Canada
    • +2 more
    Jan 20, 2023

    Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Helsinki (TILT-123, Avelumab)

    Recruiting
    • Melanoma
    • Head and Neck Squamous Cell Carcinoma
    • Helsinki, Finland
      Docrates Cancer Center
    Jul 12, 2022

    Subjects With T2D or at Risk of T2D Cohort Follow-up

    Not yet recruiting
    • Diabetes Mellitus, Type 2
    • OGTT
    • +2 more
    • Évry, France
      Centre d'Etudes et de Recherche pour l'Intensification du Traite
    Dec 23, 2022